Blood biomarkers to predict response to atezolizumab plus bevacizumab in hepatocellular carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center prospective observational cohort study enrolling patients with unresectable or advanced hepatocellular carcinoma who are starting first-line atezolizumab plus bevacizumab. Researchers will analyze baseline and longitudinal peripheral blood samples collected during routine clinical testing to explore proteomic, metabolomic, extracellular vesicle, and cell-based biomarkers. The goal is to see if these biomarkers correlate with treatment response as measured by RECIST 1.1 (with mRECIST as a supportive assessment) and to develop predictive models that identify likely responders. No experimental intervention is performed; the study relies on residual blood samples and standard clinical data collected during care. Eligible participants will be enrolled at Zhongshan Hospital, Fudan University, with analyses focused on predicting treatment benefit from T+A therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18-80 years
* Histologically or clinically confirmed unresectable or advanced HCC, classified according to the BCLC staging system
* Planned to receive first-line atezolizumab plus bevacizumab therapy, with no prior systemic therapy for unresectable or advanced HCC
* At least one measurable target lesion with a longest diameter of ≥10 mm on CT or MRI according to RECIST 1.1, with mRECIST assessment performed when applicable
* Availability of baseline and follow-up clinical and radiological data
* Willing and able to provide written informed consent

Exclusion Criteria:

* Presence of another active malignancy, except for malignancies that have been curatively treated and remain recurrence-free
* Prior systemic treatment with immune checkpoint inhibitors or anti-angiogenic agents for unresectable or advanced HCC
* Expected inability to complete the required clinical or radiological follow-up assessments
* Severe comorbid conditions that may interfere with study participation
* No qualified residual blood sample available for planned biomarker analyses because of insufficient volume, contamination, loss, or other sample-related issues
* Any condition deemed unsuitable for participation by the investigator

Where it's running

• Zhongshan Hospital, Fudan University
  Shanghai, Shanghai Municipality, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TIPS benefits for people with hepatocellular carcinoma taking Tecentriq (atezolizumab) plus Avastin (bevacizumab) as first-line therapy.

  This study will try to see if placing a TIPS device helps people with advanced or unresectable hepatocellular carcinoma who are starting first-line treatment with Tecentriq plus Avastin.

  Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Düsseldorf, North Rhine-Westphalia · NCT07365930

• FOLFOX chemotherapy with atezolizumab and bevacizumab after progression on atezolizumab plus bevacizumab for advanced liver cancer

  This trial will test whether giving FOLFOX chemotherapy together with continued atezolizumab and bevacizumab helps people with advanced hepatocellular carcinoma whose cancer progressed on prior atezolizumab plus bevacizumab.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07192185

• Preventing esophageal varices in liver cancer patients treated with specific medications

  This study is testing whether treating liver cancer patients with specific medications can help prevent the worsening of esophageal varices and reduce the risk of bleeding.

  Recruiting Tanta University · Tanta, Gharbyea · NCT06961526

• Real-life experience with immunotherapy for liver cancer treatment

  This study is testing new combinations of immunotherapy treatments for liver cancer to see how well they work and how safe they are for patients.

  Recruiting at 16 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Torrette, AN and 23 other locations · NCT06806579

• Combining radiotherapy and immunotherapy for advanced liver cancer before transplant

  This study is testing if combining radiation therapy with immunotherapy can help people with advanced liver cancer get better and qualify for a liver transplant.

  Recruiting Phase 1/2 University Health Network, Toronto · London, Ontario and 1 other locations · NCT06725121

• Evaluating RZ-001 with Valganciclovir and Atezolizumab/Bevacizumab for Liver Cancer

  This study is testing a new combination treatment for advanced liver cancer to see if it is safe and effective for patients with a specific type of the disease.

  Recruiting at 9 sites Phase 1/2 Rznomics, Inc. · Busan and 8 other locations · NCT06695026

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.